Canaccord Genuity restated their buy rating on shares of Cryolife (NYSE:CRY) in a research report sent to investors on Friday morning. The firm currently has a $28.00 target price on the medical equipment provider’s stock, up from their previous target price of $25.00.
A number of other equities analysts have also recently issued reports on CRY. Northland Securities reiterated a buy rating and set a $23.50 target price on shares of Cryolife in a report on Thursday, March 8th. ValuEngine cut Cryolife from a hold rating to a sell rating in a report on Wednesday, March 7th. Finally, Zacks Investment Research upgraded Cryolife from a sell rating to a hold rating in a report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Cryolife currently has an average rating of Hold and a consensus price target of $25.83.
Cryolife (CRY) opened at $21.55 on Friday. The stock has a market capitalization of $726.03, a PE ratio of 215.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.90 and a current ratio of 4.18. Cryolife has a 1-year low of $14.02 and a 1-year high of $24.00.
In other Cryolife news, Director C Elkins Ronald sold 2,000 shares of the stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $22.00, for a total transaction of $44,000.00. Following the completion of the transaction, the director now owns 97,849 shares in the company, valued at approximately $2,152,678. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.00% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Cryolife by 4.9% during the 4th quarter. BlackRock Inc. now owns 4,344,104 shares of the medical equipment provider’s stock worth $83,188,000 after buying an additional 204,843 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Cryolife by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,994,820 shares of the medical equipment provider’s stock worth $45,282,000 after buying an additional 34,599 shares during the last quarter. Macquarie Group Ltd. boosted its stake in shares of Cryolife by 17.4% during the 4th quarter. Macquarie Group Ltd. now owns 1,888,879 shares of the medical equipment provider’s stock worth $36,172,000 after buying an additional 279,595 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Cryolife by 6.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock worth $33,090,000 after buying an additional 102,540 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its stake in shares of Cryolife by 23.7% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 775,314 shares of the medical equipment provider’s stock worth $14,847,000 after buying an additional 148,354 shares during the last quarter. Institutional investors own 73.99% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.themarketsdaily.com/2018/03/13/cryolife-cry-receives-buy-rating-from-canaccord-genuity.html.
Cryolife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.